Takara BioFRA:TF2 71 OCF Margin % is 2.66% as of Mar. 2026, which is 79% below its 10-year median of 12.59. GuruFocus rates FRA:TF2 with a GF Score™ of 71/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Takara Bio ranks better than 75.18% on this metric.
The historical rank and industry rank for Takara Bio's OCF Margin % or its related term are showing as below:
FRA:TF2'
s OCF Margin % Range Over the Past 10 Years
Min: 3.93 Med: 12.59 Max: 47.22
Current: 9.18
During the past 13 years, the highest OCF Margin % of Takara Bio was 47.22%. The lowest was 3.93%. And the median was 12.59%.
FRA:TF2's OCF Margin % is ranked better than 75.18% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs FRA:TF2: 9.18
Takara Bio OCF Margin % Related Terms
Takara Bio OCF Margin % Historical Data
* Premium members only.
The historical data trend for Takara Bio's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Takara Bio's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Takara Bio's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio (FRA:TF2) has a OCF Margin % of 2.66% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Takara Bio and its competitors. This is 79% below median its historical median of 12.59. Over the past decade, Takara Bio's OCF Margin % has ranged from 3.93 to 47.22. According to the industry distribution chart, Takara Bio ranks #238 out of 959 companies in the Biotechnology industry, placing it in the top 24.8%.
Is Takara Bio's OCF Margin % too high?
Takara Bio's current OCF Margin % of 2.66% is 79% below median its 10-year median of 12.59. Over the past 10 years, this metric has ranged from a low of 3.93 to a high of 47.22. Based on the distribution chart, Takara Bio ranks #238 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Takara Bio has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #238 out of 959 companies for OCF Margin %. This places Takara Bio in the top 25% of its industry — outperforming the majority of peers. Historically, Takara Bio's own OCF Margin % has ranged from 3.93 to 47.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Takara Bio and its competitors. Takara Bio's current OCF Margin % is 2.66%, which is 79% below median its own 10-year median of 12.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current OCF Margin % is 2.66%, which is 79% below median its 10-year median of 12.59. Takara Bio's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current OCF Margin % is 2.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
OCF Margin %: 2.66% (79% below median its 10-year median of 12.59)
GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
71GF Score
Get the complete analysis for FRA:TF2
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
